Discordant responses to HAART in HIV-1 patients: the need to focus on intervention

References

• Marimoutou C, Chene G, Mercie P et al. Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996–1998. J. Acquir. Immune Defic. Syndr.27(2), 161–167 (2001).
   PubMed Web of Science ®Google Scholar
• Grabar S, Le Moing V, Goujard C et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann. Int. Med.133(6), 401–410 (2000).
   PubMed Web of Science ®Google Scholar
• Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatchkine MD. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J. Infect. Dis.183(9), 1328–1335 (2001).
   PubMed Web of Science ®Google Scholar
• Nicastri E, Chiesi A, Angeletti C et al. Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART. J. Med. Virol.76(2), 153–160 (2005).
   PubMed Web of Science ®Google Scholar
• Moore DM, Hogg RS, Yip B et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J. Acquir. Immune Defic. Syndr.40(3), 288–293 (2005).
   PubMed Web of Science ®Google Scholar
• Nicastri E, Sarmati L, d’Ettorre G et al. High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis. J. Clin. Microbiol.41(7), 3007–3012 (2003).
   PubMed Web of Science ®Google Scholar
• Tuboi SH, Brinkhof MW, Egger M et al. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the Antiretroviral Therapy in Low-Income Countries (ART-LINC) Collaboration. J. Acquir. Immune Defic. Syndr.45(1), 52–59 (2007).
   PubMed Web of Science ®Google Scholar
• Kaufmann GR, Furrer H, Ledergerber B et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/µl in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin. Infect. Dis.41(3), 361–372 (2005).
   PubMed Web of Science ®Google Scholar
• Lange CG, Valdez H, Medvik K, Asaad R, Lederman MM. CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin. Immunol.102(2), 154–161 (2002).
   PubMed Web of Science ®Google Scholar
• Connors M, Kovacs JA, Krevat S et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat. Med.3(5), 533–540 (1997).
   PubMed Web of Science ®Google Scholar
• Barrios A, Rendon A, Negredo E et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS19(6), 569–575 (2005).
   PubMed Web of Science ®Google Scholar
• Karrer U, Ledergerber B, Furrer H et al. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS19(17), 1987–1994 (2005).
   PubMed Web of Science ®Google Scholar
• Di Biagio A, Beltrame A, Cenderello G, Ferrea G, De Maria A. Clinically stable treatment-experienced adults receiving tenofovir and didanosine. HIV Clin. Trials7(1), 10–15 (2006).
   PubMed Web of Science ®Google Scholar
• Marchetti G, Gori A, Casabianca A et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS20(13), 1727–1736 (2006).
   PubMed Web of Science ®Google Scholar
• Alter G, Teigen N, Davis BT et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood106(10), 3366–3369 (2005).
   PubMed Web of Science ®Google Scholar
• De Maria A, Fogli M, Costa P et al. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur. J. Immunol.33(9), 2410–2418 (2003).
   PubMed Web of Science ®Google Scholar
• Fogli M, Costa P, Murdaca G et al. Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients. Eur. J. Immunol.34(8), 2313–2321 (2004).
   PubMed Web of Science ®Google Scholar
• Vankayalapati R, Klucar P, Wizel B et al. NK cells regulate CD8+ T cell effector function in response to an intracellular pathogen. J. Immunol.172(1), 130–137 (2004).
   PubMed Web of Science ®Google Scholar
• Vitale M, Della Chiesa M, Carlomagno S et al. NK-dependent DC maturation is mediated by TNFα and IFNγ released upon engagement of the NKp30 triggering receptor. Blood106(2), 566–571 (2005).
   PubMed Web of Science ®Google Scholar
• Rutjens E, Mazza S, Biassoni R et al. Differential NKp30 inducibility in chimpanzee NK cells and conserved NK cell phenotype and function in long-term HIV-1-infected animals. J. Immunol.178(3), 1702–1712 (2007).
   PubMed Web of Science ®Google Scholar
• Mastroianni CM, d’Ettorre G, Forcina G, Vullo V. Teaching tired T cells to fight HIV: time to test IL-15 for immunotherapy? Trends Immunol.25(3), 121–125 (2004).
   PubMed Web of Science ®Google Scholar
• Kaplan SS, Ferrari G, Wrin T et al. Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4+/viral load discordance. AIDS Res. Hum. Retroviruses21(1), 13–16 (2005).
   PubMed Web of Science ®Google Scholar
• Sufka SA, Ferrari G, Gryszowka VE et al. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. J. Infect. Dis.187(7), 1027–1037 (2003).
   PubMed Web of Science ®Google Scholar
• Deeks SG, Wrin T, Liegler T et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med.344(7), 472–480 (2001).
   PubMed Web of Science ®Google Scholar
• Barbour JD, Wrin T, Grant RM et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J. Virol.76(21), 11104–11112 (2002).
   PubMed Web of Science ®Google Scholar
• Equils O, Shapiro A, Madak Z, Liu C, Lu D. Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-induced NF-κB activation. Antimicrob. Agents Chemother.48(10), 3905–3911 (2004).
   PubMed Web of Science ®Google Scholar
• Piccinini M, Rinaudo MT, Anselmino A et al. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antivir. Ther.10(2), 215–223 (2005).
   PubMed Web of Science ®Google Scholar
• Markowitz N, Bebchuk JD, Abrams DI. Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2. Clin. Infect. Dis.37(8), e115–e120 (2003).
   PubMed Web of Science ®Google Scholar
• de Boer AW, Markowitz N, Lane HC et al. A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100–300 CD4+ T cells. Clin. Immunol.106(3), 188–196 (2003).
   PubMed Web of Science ®Google Scholar
• Kilby JM, Bucy RP, Mildvan D et al. A randomized, partially blinded Phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). J. Infect. Dis.194(12), 1672–1676 (2006).
   PubMed Web of Science ®Google Scholar
• Levy Y DC, Krzysiek R, Rabian C et al; ANRS 079 Study Group. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS17(3), 343–351 (2003).
   PubMed Web of Science ®Google Scholar
• Costa P, Beltrame A, De Maria A. May immunization strategies that target dendritic cells really offer advantages for HIV-1? AIDS20(9), 1351–1352 (2006).
   PubMed Web of Science ®Google Scholar
• Alpdogan O, van den Brink MR. IL-7 and IL-15: therapeutic cytokines for immunodeficiency. Trends Immunol.26(1), 56–64 (2005).
   PubMed Web of Science ®Google Scholar
• Lum JJ, Schnepple DJ, Nie Z et al. Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity. J. Virol.78(11), 6033–6042 (2004).
   PubMed Web of Science ®Google Scholar
• Napolitano LA, Grant RM, Deeks SG et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat. Med.7(1), 73–79 (2001).
   PubMed Web of Science ®Google Scholar
• Coull JJ, Turner D, Melby T, Betts MR, Lanier R, Margolis DM. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. J. Acquir. Immune Defic. Syndr.26(5), 423–434 (2001).
   PubMed Web of Science ®Google Scholar
• Sha BE, Valdez H, Gelman RS et al. Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor a, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res. Hum. Retroviruses18(9), 661–665 (2002).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Kyambadde P, Johnson JL et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS18(2), 257–264 (2004).
   PubMed Web of Science ®Google Scholar
• Rizzardi GP, Harari A, Capiluppi B et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J. Clin. Invest.109(5), 681–688 (2002).
   PubMed Web of Science ®Google Scholar
• Lederman MM, Smeaton L, Smith KY et al. Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. J. Infect. Dis.194(12), 1677–1685 (2006).
   PubMed Web of Science ®Google Scholar